Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prothrombin complex concentrates.

J A Penner

    Bibliotheca Haematologica
    |January 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Prothrombin complex products are used for inhibitor patients, but their therapeutic and thrombogenic factors remain unclear. A combination of factors, possibly protected procoagulant forms, likely causes these effects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The impact of routine cryptococcal antigen screening on survival among HIV-infected individuals with advanced immunosuppression in Kenya.

    Tropical medicine & international health : TM & IH·2013
    Same author

    Successful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosuppressive therapy.

    American journal of hematology·2002
    Same author

    Haemophilic patients with inhibitors to factor VIII or IX: variables affecting treatment response.

    Haemophilia : the official journal of the World Federation of Hemophilia·2001
    Same author

    Management of haemophilia in patients with high-titre inhibitors: focus on the evolution of activated prothrombin complex concentrate AUTOPLEX T.

    Haemophilia : the official journal of the World Federation of Hemophilia·1999
    Same author

    A simple method for detection of factor V R506Q (Leiden) mutation in dried blood spots.

    Clinica chimica acta; international journal of clinical chemistry·1999
    Same author

    Disseminated intravascular coagulation in patients with multiple organ failure of non-septic origin.

    Seminars in thrombosis and hemostasis·1998
    Same journal

    Incorporation of allosteric effectors of hemoglobin in red blood cells. Physiological effects.

    Bibliotheca haematologica·1985
    Same journal

    Resealed red blood cells as a new blood transfusion product.

    Bibliotheca haematologica·1985
    Same journal

    Entrapment of L-asparaginase in red blood cells. A strategy to improve treatment of acute lymphoblastic leukemia.

    Bibliotheca haematologica·1985
    Same journal

    G6PD encapsulation and metabolic properties of loaded erythrocytes.

    Bibliotheca haematologica·1985
    Same journal

    Entrapment of normal and mutant glucose 6-phosphate dehydrogenase (G6PD) within G6PD deficient erythrocytes.

    Bibliotheca haematologica·1985
    Same journal

    Encapsulation and pharmacokinetics of drugs in bovine and canine carrier erythrocytes.

    Bibliotheca haematologica·1985
    See all related articles

    Area of Science:

    • Hematology
    • Thrombosis Research
    • Pharmacology

    Background:

    • Inhibitor patients present unique challenges for hemostasis management.
    • Prothrombin complex products (PCPs) are utilized, but their precise mechanisms are not fully understood.
    • Thrombogenicity associated with PCPs requires careful consideration.

    Purpose of the Study:

    • To investigate the therapeutic principles of prothrombin complex products in inhibitor patients.
    • To identify factors contributing to the thrombogenicity of these products.
    • To elucidate the complex interplay between therapeutic efficacy and adverse thrombotic events.

    Main Methods:

    • Review of clinical data and product composition.
    • Analysis of potential procoagulant structures and their interactions.

    Related Experiment Videos

  • Evaluation of antithrombin III neutralization resistance.

    • Main Results:

    • Difficulty in pinpointing a single effective therapeutic principle for PCPs.
    • Evidence suggests a combination of factors underlies both therapeutic and thrombogenic effects.
    • Procoagulants may exist in protected intermediate or aggregate forms within PCPs.

    Conclusions:

    • The therapeutic and thrombogenic effects of PCPs are multifactorial.
    • Protected procoagulant forms may evade natural anticoagulation mechanisms like antithrombin III.
    • Further research is needed to optimize PCP use and mitigate thrombotic risks in inhibitor patients.